IRIS Accounts Production v25.4.0.155 SC432222 Board of Directors 1.10.24 30.9.25 30.9.25 false true false false true false Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh SC432222 2024-09-30 SC432222 2025-09-30 SC432222 2024-10-01 2025-09-30 SC432222 2023-09-30 SC432222 2023-10-01 2024-09-30 SC432222 2024-09-30 SC432222 ns15:Scotland 2024-10-01 2025-09-30 SC432222 ns14:PoundSterling 2024-10-01 2025-09-30 SC432222 ns10:Director1 2024-10-01 2025-09-30 SC432222 ns10:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 SC432222 ns10:SmallEntities 2024-10-01 2025-09-30 SC432222 ns10:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 SC432222 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-01 2025-09-30 SC432222 ns10:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 SC432222 ns10:FullAccounts 2024-10-01 2025-09-30 SC432222 ns10:OrdinaryShareClass1 2024-10-01 2025-09-30 SC432222 ns10:Director4 2024-10-01 2025-09-30 SC432222 ns10:Director5 2024-10-01 2025-09-30 SC432222 ns10:Director6 2024-10-01 2025-09-30 SC432222 ns10:RegisteredOffice 2024-10-01 2025-09-30 SC432222 ns5:CurrentFinancialInstruments 2025-09-30 SC432222 ns5:CurrentFinancialInstruments 2024-09-30 SC432222 ns5:ShareCapital 2025-09-30 SC432222 ns5:ShareCapital 2024-09-30 SC432222 ns5:SharePremium 2025-09-30 SC432222 ns5:SharePremium 2024-09-30 SC432222 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 SC432222 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 SC432222 ns5:LeaseholdImprovements 2024-10-01 2025-09-30 SC432222 ns5:FurnitureFittings 2024-10-01 2025-09-30 SC432222 ns5:LeaseholdImprovements 2024-09-30 SC432222 ns5:FurnitureFittings 2024-09-30 SC432222 ns5:LeaseholdImprovements 2025-09-30 SC432222 ns5:FurnitureFittings 2025-09-30 SC432222 ns5:LeaseholdImprovements 2024-09-30 SC432222 ns5:FurnitureFittings 2024-09-30 SC432222 ns5:CostValuation 2024-09-30 SC432222 ns5:AdditionsToInvestments 2025-09-30 SC432222 ns5:CostValuation 2025-09-30 SC432222 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 SC432222 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-09-30 SC432222 ns10:OrdinaryShareClass1 2025-09-30

REGISTERED NUMBER: SC432222 (Scotland)

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 30 SEPTEMBER 2025 |

| FOR |

| RESOLVE MEDICOLEGAL LIMITED |

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

RESOLVE MEDICOLEGAL LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 30 SEPTEMBER 2025

| DIRECTORS: | Mr M Broadbent

| Mr R A E Clayton

| Mrs C F Provan

| Mr R L Carter

| REGISTERED OFFICE: | The Hub

| 3 Earl Haig Road

| Glasgow

| Scotland

| G52 4JU

| REGISTERED NUMBER: | SC432222 (Scotland)

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

BALANCE SHEET

30 SEPTEMBER 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 15,786 |  | 15,927 |  |

Investments | 5 | 15,035 |  | 35 |  |

30,821 |  | 15,962 |  |

CURRENT ASSETS

Debtors | 6 | 527,714 |  | 523,902 |  |

Cash at bank | 426,619 |  | 145,264 |  |

954,333 |  | 669,166 |  |

CREDITORS

Amounts falling due within one year | 7 | 229,335 |  | 162,037 |  |

NET CURRENT ASSETS | 724,998 |  | 507,129 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 755,819 |  | 523,091 |  |

PROVISIONS FOR LIABILITIES | 3,283 |  | 3,318 |  |

NET ASSETS | 752,536 |  | 519,773 |  |

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

BALANCE SHEET - continued

30 SEPTEMBER 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

CAPITAL AND RESERVES

Called up share capital | 8 | 110 |  | 110 |  |

Share premium | 99,990 |  | 99,990 |  |

Retained earnings | 652,436 |  | 419,673 |  |

SHAREHOLDERS' FUNDS | 752,536 |  | 519,773 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22 December 2025 and were signed on its behalf by:

Mr M Broadbent - Director

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

1. | STATUTORY INFORMATION

| Resolve Medicolegal Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| BASIS OF PREPARING THE FINANCIAL STATEMENTS

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| RELATED PARTY EXEMPTION

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| TURNOVER

| The turnover shown in the profit and loss account represents amount earned during the year and is recognised when the company obtains the right to consideration.

| TANGIBLE FIXED ASSETS

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

| Improvements to property | - | 20% on cost

| Fixtures and fittings | - | 15% on reducing balance

| All fixed assets are initially recorded at cost.

| INVESTMENTS IN SUBSIDIARIES

| Investments in subsidiary undertakings are recognised at cost.

| TAXATION

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

2. | ACCOUNTING POLICIES - continued

| DEFERRED TAX

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 18 (2024 - 17 ) .

4. | TANGIBLE FIXED ASSETS

| Improvements |  | Fixtures |

| to |  | and |

| property |  | fittings |  | Totals

£ | £ | £ |

| COST

| At 1 October 2024 | 20,346 |  | 37,585 |  | 57,931 |  |

| Additions | - |  | 2,645 |  | 2,645 |  |

| At 30 September 2025 | 20,346 |  | 40,230 |  | 60,576 |  |

| DEPRECIATION

| At 1 October 2024 | 20,346 |  | 21,658 |  | 42,004 |  |

| Charge for year | - |  | 2,786 |  | 2,786 |  |

| At 30 September 2025 | 20,346 |  | 24,444 |  | 44,790 |  |

| NET BOOK VALUE

| At 30 September 2025 | - |  | 15,786 |  | 15,786 |  |

| At 30 September 2024 | - |  | 15,927 |  | 15,927 |  |

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

5. | FIXED ASSET INVESTMENTS

| Shares in |

| group |  | Other |

| undertakings |  | investments |  | Totals

£ | £ | £ |

| COST

| At 1 October 2024 | 35 |  | - |  | 35 |  |

| Resolve Hub Limited shares | - |  | 15,000 |  | 15,000 |  |

| At 30 September 2025 | 35 |  | 15,000 |  | 15,035 |  |

| NET BOOK VALUE

| At 30 September 2025 | 35 |  | 15,000 |  | 15,035 |  |

| At 30 September 2024 | 35 |  | - |  | 35 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 125,677 |  | 121,673 |  |

| Amounts owed by associates | 395,887 |  | 395,887 |  |

| Directors' current accounts | 1,000 |  | - |  |

| Prepayments and accrued income | 5,150 |  | 6,342 |  |

527,714 |  | 523,902 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Tax | 111,085 |  | 68,232 |  |

| VAT | 73,857 |  | 54,231 |  |

| Accrued expenses | 44,393 |  | 39,574 |  |

229,335 |  | 162,037 |  |

8. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | £1 | 110 |  | 110 |  |

RESOLVE MEDICOLEGAL LIMITED (REGISTERED NUMBER: SC432222)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 SEPTEMBER 2025

9. | RELATED PARTY DISCLOSURES

| Throughout the year the company paid £18,000 (2024 - £18,000) to Broadbent Legal Services Limited, a company in which Mr Broadbent is a Director and Shareholder, for Management Consultancy. The balance owing as at the balance sheet date was £Nil (2024 - £Nil).

| Throughout the year the company paid £2,000 (2024 - £6,000) to Simpsons Orthopaedics Limited, a company in which Mr Simpson is a Director and Shareholder, for Management Consultancy.. As of February 2025 Simpson Orthopaedics ceased to be a Director.

| Throughout the year the company paid £2,500 (2024 - £6,000) to Mr D Donaldson for Management Consultancy. As of February 2025, Mr D Donaldson ceased to be a Director,.

| Throughout the year the company paid £6,000 (2024 - £6,000) to Clayton Medical, a company in which Mr Clayton is a Director and Shareholder, for Management Consultancy. The balance owing as at the balance sheet date was £Nil (2024 - £Nil).

| As of April 2025, the company paid £3,500.00 to Mr R Carter for Management Consultancy. The balance owing as at the balance sheet date was £Nil.